Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium
Morra, Anna , Jung, Audrey , Behrens, Sabine , Keeman, Renske , Ahearn, Thomas U. , Arndt, Volker , Augustinsson, Annelie , Auvinen, Päivi , Becher, Heiko , Beckmann, Matthias W. , Bojesen, Stig E. , Bolla, Manjeet K. , Brenner, Hermann , Camp, Nicola J. , Campa, Daniele , Castelao, Jose E. , Choi, Ji‐Yeob , Cox, Angela , Easton, Douglas F. , Eccles, Diana M., Egan, Kathleen M. , Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, Gago-Domínguez, Manuela , Gapstur, Susan M. , Gaudet, Mia M. , Grip, Mervi, Guénel, Pascal , Haiman, Christopher A. , Håkansson, Niclas , Hamann, Ute, Hartman, Mikael , Heyworth, Jane , Hoppe, Reiner , Hopper, John L. , Hunter, David J. , Jager, Agnes , Jakimovska, Milena , Janni, Wolfgang , Koutros, Stella , Kristensen, Vessela N. , Lambrechts, Diether , Li, Jingmei , Lindblom, Annika , Mannermaa, Arto , Manoochehri, Mehdi, Margolin, Sara , Mariapun, Shivaani, Mavroudis, Dimitrios, Muranen, Taru , Newman, William G. , Noh, Dong‐Young , Nordestgaard, Børge G. , Obi, Nadia , Olsson, Håkan , Park‐Simon, Tjoung‐Won , Petridis, Christos , Plaseska‐Karanfilska, Dijana , Rashid, Muhammad Usman , Rennert, Gad , Rennert, Gad , Rhenius, Valerie , Romero, Atocha , Saloustros, Emmanouil , Sawyer, Elinor J. , Schneeweiß, Andreas , Schwentner, Lukas , Shah, Mitul , Shen, Chen‐Yang , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Torres, Diana , Vachon, Celine M. , Wang, Qin , Wang, Sophia , Williams, Justin A. , Winqvist, Robert , Wu, Anna H. , Yoo, Keun-Young, Yu, Jyh‐Cherng , Zheng, Wei , Yang, Xiaohong R. , Eliassen, A. Heather , García‐Closas, Montserrat , Teo, Soo‐Hwang , Chang‐Claude, Jenny , Eccles, Diana , Khaw, Kay‐Tee , Lambrechts, Diether , Arndt, Volker , Augustinsson, Annelie , Brenner, Hermann , Camp, Nicola J , Canzian, Federico , Cox, Angela , Dunning, Alison M , Evans, D Gareth , Fasching, Peter A , Gago-Dominguez, Manuela , García-Sáenz, José A , Gaudet, Mia M , Giles, Graham G , Guénel, Pascal , Hall, Per N , Hart, Steven N , Hartman, Mikael , Ito, Hidemi , Jager, Agnes , Jakubowska, Anna , Janni, Wolfgang , Kaaks, Rudolf , Kapoor, Pooja Middha , Koutros, Stella , Lambrechts, Diether , Li, Jingmei , Matsuo, Keitaro , Milne, Roger L , Muranen, Taru A , Newman, William G , Park-Simon, Tjoung-Won , Pharoah, Paul D P , Rennert, Gad , Rennert, Gad , Rhenius, Valerie , Romero, Atocha , Saloustros, Emmanouil , Schneeweiss, Andreas , Scott, Christopher , Southey, Melissa C , Stram, Daniel O. , Tamimi, Rulla M , Tomlinson, Ian , Torres, Diana , Vachon, Celine M. , Wolk, Alicja , Ziogas, Argyrios , Holmes, Michelle D , García-Closas, Montserrat , Teo, Soo H , Schmidt, Marjanka K , Chang-Claude, Jenny , Lambrechts, Diether , Behrens, Sabine , Eccles, Diana , Keeman, Renske , Zheng, Wei , Wang, Sophia S , Jung, Audrey Y , Becher, Heiko , Eliassen, A Heather , Håkansson, Niclas , Rashid, Muhammad U , Bojesen, Stig E , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Anton‐Culver, Hoda , Freeman, Laura E. Beane , Blomqvist, Carl , Briceño, Ignacio , Brucker, Sara Yvonne , Canzian, Federico , Chanock, Stephen Jacob , Clarke, Christine L. , Couch, Fergus J. , Cross, Simon S. , Czene, Kamila , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , García-Sáenz, José Á. , Giles, Graham G. , Han, Sileny , Hart, Steven N. , Ito, Hidemi , Jakubowska, Anna , Kaaks, Rudolf , Kang, Daehee , Middha, Pooja , Kitahara, Cari M. , Kraft, Peter , Lacey, James V. , Marchand, Loı̈c Le , Lubiński, Jan , Lush, Michael J. , Manoochehri, Mehdi, Matsuo, Keitaro , Milne, Roger L. , Olshan, Andrew F. , Pharoah, Paul D.P. , Presneau, Nadège , Scott, Christopher G. , Shu, Xiao‐Ou , Southey, Melissa C. , Tamimi, Rulla M. , Tapper, William , Troester, Melissa A. , Truong, Thérèse , Wolk, Alicja , Ziogas, Argyrios , Schmidt, Marjanka K.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 26, 2021 | Volume: 30 | Issue: 4 | Pages: 623-642

10.1158/1055-9965.epi-20-0924 | PMID 33500318 Get It

Abstract Background: It is not known whether modifiable lifestyle factors that predict survival after invasive breast cancer differ by subtype. Methods: We analyzed data for 121,435 women diagnosed with breast cancer from 67 studies in the Breast Cancer Association Consortium with 16,890 deaths (8,554 breast cancer specific) over 10 years. Cox regression was used to estimate associations between risk factors and 10-year all-cause mortality and breast cancer–specific mortality overall, by estrogen receptor (ER) status, and by intrinsic-like subtype. Results: There was no evidence of heterogeneous associations between risk factors and mortality by subtype (Padj > 0.30). The strongest associations were between all-cause mortality and BMI ≥30 versus 18.5–25 kg/m2 [HR (95% confidence interval (CI), 1.19 (1.06–1.34)]; current versus never smoking [1.37 (1.27–1.47)], high versus low physical activity [0.43 (0.21–0.86)], age ≥30 years versus <20 years at first pregnancy [0.79 (0.72–0.86)]; >0–<5 years versus ≥10 years since last full-term birth [1.31 (1.11–1.55)]; ever versus never use of oral contraceptives [0.91 (0.87–0.96)]; ever versus never use of menopausal hormone therapy, including current estrogen–progestin therapy [0.61 (0.54–0.69)]. Similar associations with breast cancer mortality were weaker; for example, 1.11 (1.02–1.21) for current versus never smoking. Conclusions: We confirm associations between modifiable lifestyle factors and 10-year all-cause mortality. There was no strong evidence that associations differed by ER status or intrinsic-like subtype. Impact: Given the large dataset and lack of evidence that associations between modifiable risk factors and 10-year mortality differed by subtype, these associations could be cautiously used in prognostication models to inform patient-centered care.
Five Wrist Operations That Give the Best Results
Maldonado, Andrés A. , Rhee, Peter C. , Pulos, Nicholas , Shin, Alexander Y. , Maldonado, Andres A.

Mayo Clinic

Plastic & Reconstructive Surgery | January 26, 2021 | Volume: 147 | Issue: 2 | Pages: 295e-302e

10.1097/prs.0000000000007521 | PMID 33565837 Get It

Learning Objectives: After reading this article and viewing the videos, the participant should be able to: 1. Recognize the following five wrist operations as consistent options for different wrist injuries: carpal tunnel release, medial femoral condyle bone flap for scaphoid nonunion associated with carpal collapse and avascular necrosis, scaphocapitate arthrodesis for Kienböck disease, percutaneous screw fixation of nondisplaced scaphoid fracture, and four-corner arthrodesis. 2. Know the state-of-the-art of these five procedures. 3. State the indications of each operation. 4. List the surgical steps of these five procedures. Summary: The wrist is a complex joint that concentrates different types of tissues (e.g., bone, cartilage, ligaments, nerves, vessels) and a broad different spectrum of diseases. Treatment of wrist injuries has improved during recent years, mainly because of improvement in strategy, techniques, microsurgical equipment, understanding anatomy and improvements in technology. In this article, we present the five operations (i.e., carpal tunnel release, medial femoral condyle bone flap for scaphoid nonunion associated with carpal collapse and avascular necrosis, scaphocapitate arthrodesis for Kienböck disease, percutaneous screw fixation of nondisplaced scaphoid fracture, and four-corner arthrodesis) that have consistently given good outcomes in patients suffering from different wrist injuries/maladies.
Mechanical Assessment of Tissue Properties During Tourniquet Application
Hooke, Alexander W. , Lowndes, Bethany R. , Hallbeck, M. Susan , Prytz, Erik , Jonson, Carl‐Oscar

Mayo Clinic

Military Medicine | January 26, 2021 | Volume: 186 | Issue: Supplement_1 | Pages: 378-383

10.1093/milmed/usaa266 | PMID 33499441 Get It

ABSTRACTIntroductionSuccessful tourniquet application increases survival rate of exsanguinating extremity hemorrhage victims. Tactile feedback during tourniquet application training should reflect human tissue properties in order to increase success in the field. This study aims to understand the mechanical properties of a human limb during tourniquet application.MethodSix cadaveric extremities—three uppers and three lowers—were tested from three body mass index groups: low (<19) healthy (19-24), and overweight (>24). Each specimen donned with a tourniquet and mounted to a servo-hydraulic testing machine, which enabled controlled tightening of the tourniquet while recording the tourniquet tension force and strap displacement. A thin-film pressure sensor placed between the specimen and the tourniquet recorded contact pressure. Each limb was tested with the tourniquet applied at two different sites resulting in testing at the upper arm, forearm, thigh, and shank.ResultsThe load displacement curves during radial compression were found to be nonlinear overall, with identifiable linear regions. Average contact pressure under the tourniquet strap at 200N and 300N of tension force was 126.3 (σ = 41.2) mm Hg and 205.3 (σ = 75.3) mm Hg, respectively. There were no significant differences in tissue stiffness or contact pressure at 300N of tension force between limb (upper vs. lower) or body mass index. At 200N of tension, the upper limb had significantly higher contact pressure than the lower limb (P = 0.040). Relative radial compression was significantly different between upper (16.74, σ = 4.16%) and lower (10.15, σ = 2.25%) extremities at 200N tension (P = 0.005).ConclusionsSimulation of tissue compression during tourniquet application may be achieved with a material exhibiting elastic properties to mimic the force-displacement behavior seen in cadaveric tissue or with different layers of material. Different trainers for underweight, healthy, and overweight limbs may not be needed. Separate tourniquet training fixtures should be created for the upper and lower extremities.
A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
Kim, Alexander Y. , Toskich, Beau M, Mody, Kabir , Stein, Stacey , Goff, Laura W. , Parikh, Nainesh, Johnson, Daniel , Iyer, Renuka , Petroziello, Michael, Krishnamurthi, Smitha , Martin, Charles E. , Jiang, Yixing , Akhter, Nabeel , He, Aiwu Ruth , Kim, Kevin , Goyal, Lipika , Abrams, Thomas A. , Brown, Daniel B. , Kim, Richard D. , Sandow, Tyler Allan

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: TPS358-TPS358

10.1200/jco.2021.39.3_suppl.tps358 Get It

TPS358 Background: The anti–PD-L1 antibody ATEZO prevents PD-L1 from interacting with PD-1 and B7.1, thus reinvigorating antitumor T cell activity. Anti-VEGF BEV can increase dendritic cell maturation, enhance T cell infiltration, and reduce myeloid-derived suppressor cells and regulatory T-cells in tumors. This combination has been FDA approved for first-line treatment of advanced HCC based on the IMbrave 150 study. On the other hand, locoregional radiotherapy (e.g., Y90 TARE) enhances the diversity of the intratumoral T cell receptor repertoire. It is the standard of care for pts with intermediate-stage HCC (iHCC). Based on preclinical and clinical data, we hypothesize that the combination of Y90 TARE, BEV, and ATEZO induces synergistic tumor-killing. Methods: This is an open-label, multicenter, randomized phase II study of Y90 TARE and BEV plus ATEZO compared with Y90 TARE alone in pts with unresectable IHCC. The primary study objective is to assess and compare the progression-free survival (PFS) (per mRECIST 1.1) of pts in each arm. The main secondary objective is to determine the safety and tolerability (CTCAE v5) of TARE combined with ATEZO and BEV in pts with HCC. Exploratory objectives are to assess the role of the immunoscore and PD-L1 expression levels in the prediction of improved clinical outcome in pts receiving Y-90 TARE and BEV plus ATEZO; the composition of tumor-infiltrating immune cell subtypes in predicting response to a chosen therapy; how Y90 therapy affects the proportion of antigen-presenting cells in the tumor; and symptoms experienced by pts receiving TARE and BEV plus ATEZO treatment, using patient-reported outcomes. Eligible pts have either HCC that is not amenable to surgical resection, confirmed by pathology review, or at least BCLC stage B HCC outside of downstaging criteria. Other standard eligibility criteria apply. Pts must have a pretreatment liver biopsy taken and then be randomized 1:1 to TARE (Arm A) or TARE followed by ATEZO and BEV (Arm B). Pts will have TARE mapping during week (wk) 1 and TARE treatment during wk 2. In Arm B, pts will start BEV plus ATEZO 4 wks (±1 wk) after TARE treatment. Pts will have abdominal MRI or CT scans every 12 weeks, CT scans of the chest every 24 wks, and a second tumor biopsy at 4 wks. Disease progression will be captured by both RECIST 1.1 and mRECIST. We plan to assess the safety of TARE with BEV and ATEZO in the first 10 pts randomized to Arm B for two cycles. If there are no grade ≥ 3 unexpected toxicities possibly, probably or definitely related to combined TARE plus BEV plus ATEZO, the study will continue to accrue 128 pts in total. Pts will continue study treatment (Arm B) for a total of 24 months from initiation of TARE or until intolerable toxicity or disease progression occur, whichever is earlier. Enrollment began in September 2020. Clinical trial information: NCT04541173.
Identifying Malignant Lymph Nodes of Prostate Cancer Patients Using A Combination of Pre-Trained Deep Models and Traditional Machine Learning Classifiers
Sarkar, Suryadipto , Harwood, Matthew , Silva, Alvin, Wu, Teresa

Mayo Clinic

No container title available | January 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-143996/v1 Get It

Abstract Prostate cancer is the second most common new cancer diagnosis in the United States. The prostate gland sits beneath the urinary bladder and surrounds the first part of the urethra. Usually, prostate cancer is slow-growing; stays confined to the prostate gland; and can be treated conservatively (active surveillance) or with surgery. However, if the cancer has spread beyond the prostate, such as to the lymph nodes, then that suggests the cancer is more aggressive and surgery is not adequate. In those cases, radiation and/or systemic therapies (e.g., chemotherapy, immunotherapy) are required. The challenge is that it is often difficult for radiologists to differentiate malignant lymph nodes from non-malignant ones with current medical imaging technology. In this study, we design a scalable hybrid approach utilizing a deep learning model to extract features into a machine learning classifier to automatically identify malignant lymph nodes in patients with prostate cancer.
In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes
Ravindran, Aishwarya , Fervenza, Fernando C. , Nasr, Samih H. , Alexander, Mariam P., Fidler, Mary E., Hernandez, Loren P. Herrera , Zhang, Pingchuan , Grande, Joseph P. , Cornell, Lynn D. , Gross, Lou Ann, Negron, Vivian , Jenson, Grace E., Charlesworth, M. Cristine , Sethi, Sanjeev , Herrera Hernandez, Loren P, Sethi, Sanjeev , Fervenza, Fernando C , Ravindran, Aishwarya , Cornell, Lynn , Moura, Marta Casal , Gross, LouAnn, Madden, Benjamin J. , Charlesworth, M. Cristine

Mayo Clinic

Journal of the American Society of Nephrology | January 21, 2021 | Volume: 32 | Issue: 3 | Pages: 695-706

10.1681/asn.2020081181 | PMID 33478971 Get It

Significance Statement Approximately 20% of patients with lupus nephritis, the most common renal manifestation of systemic lupus erythematosus, show membranous lupus nephritis on kidney biopsy, and nearly 10% eventually develop ESKD. Recently, two proteins, Exostosin 1 and Exostosin 2 (EXT1/EXT2), were shown to be present in a subset of membranous lupus nephritis kidney biopsy specimens. In an examination of 374 membranous lupus nephritis kidney biopsy specimens, the authors found 32.6% to be EXT1/EXT2-positive. Kidney biopsy specimens from patients with EXT1/EXT2-positive membranous lupus nephritis showed less chronicity features (glomerulosclerosis, interstitial fibrosis, and tubular atrophy) compared with those from EXT1/EXT2-negative patients. EXT1/EXT2-negative patients were also more likely to reach ESKD than EXT1/EXT2-positive patients. These findings suggest that the presence of EXT1/EXT2 is favorable, and that EXT1/EXT2-positive patients have better renal outcomes compared with EXT1/EXT2-negative patients. Background In patients with secondary (autoimmune) membranous nephropathy, two novel proteins, Exostosin 1 and Exostosin 2 (EXT1/EXT2), are potential disease antigens, biomarkers, or both. In this study, we validate the EXT1/EXT2 findings in a large cohort of membranous lupus nephritis. Methods We conducted a retrospective cohort study of patients with membranous lupus nephritis, and performed immunohistochemistry studies on the kidney biopsy specimens against EXT1 and EXT2. Clinicopathologic features and outcomes of EXT1/EXT2-positive versus EXT1/EXT2-negative patients were compared. Results Our study cohort included 374 biopsy-proven membranous lupus nephritis cases, of which 122 (32.6%) were EXT1/EXT2-positive and 252 (67.4%) were EXT1/EXT2-negative. EXT1/EXT2-positive patients were significantly younger ( P =0.01), had significantly lower serum creatinine levels ( P =0.02), were significantly more likely to present with proteinuria ≥3.5 g/24 h ( P =0.009), and had significantly less chronicity features (glomerulosclerosis, P =0.001 or interstitial fibrosis and tubular atrophy, P <0.001) on kidney biopsy. Clinical follow-up data were available for 160 patients, of which 64 (40%) biopsy results were EXT1/EXT2-positive and 96 (60%) were EXT1/EXT2-negative. The proportion of patients with class 3/4 lupus nephritis coexisting with membranous lupus nephritis was not different between the EXT1/EXT2-positive and EXT1/EXT2-negative groups (25.0% versus 32.3%; P= 0.32). The patients who were EXT1/EXT2-negative evolved to ESKD faster and more frequently compared with EXT1/EXT2-positive patients (18.8% versus 3.1%; P =0.003). Conclusions The prevalence of EXT1/EXT2 positivity was 32.6% in our cohort of membranous lupus nephritis. Compared with EXT1/EXT2-negative membranous lupus nephritis, EXT1/EXT2-positive disease appears to represent a subgroup with favorable kidney biopsy findings with respect to chronicity indices. Cases of membranous lupus nephritis that are EXT1/EXT2-negative are more likely to progress to ESKD compared with those that are EXT1/EXT2-positive.
Gastric ablation as a novel technique for modulating electrical conduction in the in vivo stomach
Aghababaie, Zahra , Paskaranandavadivel, Niranchan , Chan, Chih-Hsiang Alexander , Du, Peng , Asirvatham, Samuel J. , Farrugia, Gianrico , O’Grady, Gregory , Cheng, Leo K. , Angeli, Timothy R. , Farrugia, Gianrico , Angeli-Gordon, Timothy R , Asirvatham, Samuel J , Paskaranandavadivel, Niranchan , Amirapu, Satya , Beyder, Arthur

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | January 20, 2021 | Volume: 320 | Issue: 4 | Pages: G573-G585

10.1152/ajpgi.00448.2020 | PMID 33470186 Get It

This study presents gastric ablation as a new method for modulating slow wave activation and propagation in vivo, by creating localized electrical conduction blocks in the stomach, validated by high-resolution electrical mapping and histological tissue analysis. The results define the effective energy dose range for creating conduction blocks, while maintaining the mucosal and submucosal integrity, and demonstrate the electrophysiological effects of ablation. In future, gastric ablation can now be translated toward disrupting dysrhythmic slow wave activation.
Paraplegia Due to Aortic Occlusion from a Fungal Ball
Natteru, Prashant , Mishra, Aditi , Nair, Lakshmi Ramachandran , Auchus, Alexander P. , Natteru, Prashant A , Ramachandran Nair, Lakshmi

Mayo Clinic

Journal of Clinical Neurology | January 20, 2021 | Volume: 17 | Issue: 1 | Pages: 150

10.3988/jcn.2021.17.1.150 | PMID 33480216 Get It

Proteome Study of Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis Skin Lesions Reveals IL-16 Is Differentially Upregulated in CLE
Niewold, Timothy B. , Meves, Alexander , Popovic-Silwerfeldt, Karin, Häyry, Aliisa, Söderlund-Matell, Therese, Charlesworth, M. Cristine , Oke, Vilija , Lehman, Julia S. , Madden, Benjamin J. , Lundberg, Ingrid E. , Wahren‐Herlenius, Marie , Svenungsson, E

Mayo Clinic

No container title available | January 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-145148/v1 Get It

Abstract Background: The objective of the study was to explore disease pathways activated in the inflammatory foci of skin lesions in cutaneous lupus erythematosus (CLE) and dermatomyositis (DM). Methods: Skin biopsies acquired from active CLE and DM lesions, patient (PC) and also healthy controls (HC) were investigated. Biopsy sections were examined by a pathologist and inflammatory foci were laser micro-dissected, captured and proteins within captured tissue were detected in a hypothesis free manner by mass-spectrometry. Protein pathway analysis was performed by string-db.org platform. Findings of interest were confirmed by immunohistochemistry (IHC).Results: Proteome investigation identified interleukin (IL)-16 to be the only detectable and abundant cytokine differentially expressed in CLE compared to DM. Caspase-3, enzyme that cleaves IL-16 into its active form, was detected in low levels. Significantly higher proportion of IL-16 and Caspase-3 positive cells were identified in CLE lesions in comparison to DM, PC and HC. Interferon-regulated proteins (IRP) were abundant in both CLE and DM. Proteomic results indicate more abundant complement deposition in CLE skin lesions. Conclusions: Using hypothesis free mass-spectrometry investigation of CLE inflammatory infiltrates, we identified that IL-16 is the only detectable and highly abundant cytokine, while IRP was a common feature of both CLE and DM. IHC confirmed high expression of IL-16 and caspase-3 in CLE. Our novel molecular findings indicate that IL-16 detection could be useful in differential diagnostics between the two conditions that can display similar histopathological appearance. Potentially, IL-16 could be of interest as a future therapeutic target for CLE.
Outcomes of Open and Endoscopic Repairs of Chronic Partial- and Full-Thickness Proximal Hamstring Tendon Tears: A Multicenter Study With Minimum 2-Year Follow-up
Annin, Shawn , Lall, Ajay C. , Krych, Aaron J. , Athey, Alexander G., Spinner, Robert J. , Hartigan, David E. , Emblom, Benton A. , Ryan, Michael K. , Domb, Benjamin G. , Krych, Aaron J , Maldonado, David R.

Mayo Clinic

The American Journal of Sports Medicine | January 15, 2021 | Volume: 49 | Issue: 3 | Pages: 721-728

10.1177/0363546520981767 | PMID 33449797 Get It

Background: The preponderance of literature on the repair of proximal hamstring tendon tears focuses on the acute phase (<4 weeks). As such, there is a paucity of data reporting on the outcomes of chronic proximal hamstring tears. Purpose: To report minimum 2-year postoperative patient-reported outcome (PRO) scores, visual analog scale (VAS) for pain, and patient satisfaction from patients who underwent open or endoscopic repair of partial- and full-thickness chronic proximal hamstring tendon tears. Study Design: Case series study; Level of evidence, 4. Methods: Between April 2002 and May 2017, prospectively collected data from 3 tertiary care institutions were retrospectively reviewed for patients who underwent open and endoscopic repair of partial- and full-thickness chronic proximal hamstring tendon tears. Patients were included only if they had a chronic proximal hamstring tear (defined as ≥4 weeks from symptom onset to surgery). Patients were excluded if they had a tear treated <4 weeks after injury, underwent hamstring reconstruction, or claimed workers’ compensation. Patients who reported minimum 2-year follow-up for VAS, patient satisfaction, and the following PROs had their outcomes analyzed: the modified Hip Harris Score, Non-arthritic Hip Score, iHOT-12 (International Hip Outcome Tool), and Hip Outcome Score–Sports Specific Subscale. Results: Fifty patients (34 females and 16 males) were included in this study. There were 19 endoscopic repairs and 31 open repairs. Within the cohort, 52.0% had a full-thickness tendon tear on magnetic resonance imaging, and 48.0% had a partial tear. Average follow-up time was 58.07 ± 37.27 months (mean ± SD; range, 24-220 months). The mean age and body mass index of the group were 46.13 ± 13 years and 25.43 ± 5.14. The average time from injury to surgery was 66.73 weeks (range, 5.14-215.14 weeks). Average postoperative PROs were as follows: modified Hip Harris Score, 91.94 ± 9.96; Non-arthritic Hip Score, 91.33 ± 9.99; iHOT-12, 87.17 ± 17.54; Hip Outcome Score–Sports Specific Subscale, 87.15 ± 18.10; and VAS, 1.16 ± 1.92. Patient satisfaction was 8.22 ± 1.20. Conclusion: Patients who underwent open and endoscopic repairs for chronic partial- and full-thickness proximal hamstring tendon tears reported high PROs and satisfaction at a minimum 2-year follow-up with low rates of complications.